Jones Patrick, Elmussareh Muhammad, Aboumarzouk Omar M, Mucksavage Phillip, Somani Bhaskar K
Department of Urology, University Hospital Southampton, Southampton, UK.
Department of Urology, Pinderfields Hospital, Aberford Rd, Wakefield, UK.
Curr Urol Rep. 2018 Mar 7;19(4):27. doi: 10.1007/s11934-018-0764-5.
The role of PCNL and the expertise surrounding it has expanded in recent decades. Miniaturisation of equipment and instrument size has formed a part of this innovation. Although an increasing number of studies have been performed on miniaturised PCNL (Mi-PCNL) recently, a critical appraisal on these is lacking. We therefore conducted a systematic review of the literature to evaluate the efficacy, safety and feasibility of Mi-PCNL techniques (< 15 Fr).
A systematic review was conducted from 1990 to March 2017 on outcomes of Mi-PCNL [micro PCNL (m-PCNL) and ultra-mini PCNL (UMP)] in adult patients. Ten studies (three on m-PCNL and seven on UMP) were included in our study. Across the three studies, 118 patients (mean age 42.2 years, male to female ratio 1.3:1) underwent m-PCNL (4.8 Fr). For a mean stone size of 13.9 mm, a mean stone-free rate (SFR) was 89% and an overall complication rate was 15.2% [Clavien classification I (44%), II (28%), III (28%)], with no Clavien IV or V complications. Across the seven studies, 262 patients (mean age 49.4 years, male to female ratio 1.5:1) underwent UMP (13-14 Fr). For a mean stone size of 18.6 mm, a mean SFR was 88.3% and an overall complication rate was 6.2% [Clavien classification I (57%), II (36%), III (7%)], with no Clavien IV or V complications. While the transfusion rates for m-PCNL was 0.85%, only one case each in m-PCNL and UMP needed conversion to mini PCNL. Our review shows that for small- to medium-sized renal stones, Mi-PCNL can yield good stone-free rates whilst maintaining a low morbidity associated with it. There were no Clavien > III complications and no mortality with only one transfusion reported from this minimally invasive technique.
近几十年来,经皮肾镜取石术(PCNL)及其相关专业技术的作用不断扩展。设备和器械尺寸的小型化是这一创新的一部分。尽管最近对小型化PCNL(Mi-PCNL)进行了越来越多的研究,但缺乏对这些研究的批判性评价。因此,我们对文献进行了系统综述,以评估Mi-PCNL技术(<15F)的疗效、安全性和可行性。
对1990年至2017年3月期间成年患者Mi-PCNL(微通道经皮肾镜取石术(m-PCNL)和超微通道经皮肾镜取石术(UMP))的结果进行了系统综述。我们的研究纳入了10项研究(3项关于m-PCNL,7项关于UMP)。在这3项研究中,118例患者(平均年龄42.2岁,男女比例1.3:1)接受了m-PCNL(4.8F)。结石平均大小为13.9mm时,平均无石率(SFR)为89%,总体并发症发生率为15.2%[Clavien分级I级(44%),II级(28%),III级(28%)],无Clavien IV级或V级并发症。在这7项研究中,262例患者(平均年龄49.4岁,男女比例1.5:1)接受了UMP(13-14F)。结石平均大小为18.6mm时,平均SFR为88.3%,总体并发症发生率为6.2%[Clavien分级I级(57%),II级(36%),III级(7%)],无Clavien IV级或V级并发症。m-PCNL的输血率为0.85%,m-PCNL和UMP各只有1例需要转为迷你PCNL。我们的综述表明,对于中小型肾结石,Mi-PCNL可以获得良好的无石率,同时保持较低的发病率。没有Clavien>III级并发症,也没有死亡病例,这种微创技术仅报告了1例输血。